FINANCINGS

Akari Therapeutics plc closed a private placement for gross proceeds of approximately $75 million.

Artax Biopharma Inc. raised $10 million from a series B round of financing.

Casi Pharmaceuticals Inc. entered into definitive agreements for a $25.1 million financing.

Deciphera Pharmaceuticals LLC raised $75 million from a series B round.

Edge Therapeutics Inc. set terms for its IPO planning to offer about 5.67 million shares priced in a range of $14 to $16, for proceeds of up to $104.3 million, including overallotments.

Intra-Cellular Therapies Inc. priced its public offering with net proceeds expected to be approximately $284.7 million.

Mirna Therapeutics Inc. set terms for its IPO, planning to offer 4.65 million shares of common stock at $13 to $15 per share.

Nabriva Therapeutics AG grossed $92.25 million from an IPO.

Regenxbio Inc. closed its IPO for gross proceeds of approximately $159.4 million.

Replimune Ltd. closed a $30 million series A round.

Strongbridge Biopharma plc set terms for its IPO seeking to raise up to $87.6 million.

DEALS

AC Immune SA is collaborating with the Nestlé Institute of Health Sciences SA to develop a minimally invasive tau diagnostic assay for the early diagnosis of Alzheimer's disease.

Ani Pharmaceuticals Inc. is acquiring the new drug applications for purified corticotropin gel and corticotropin-zinc hydroxide from Merck & Co. Inc.

Bind Therapeutics Inc. said Pfizer Inc. exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors.

Glide Pharmaceutical Technologies Ltd. is collaborating with Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, Ciflu.

H3 Biomedicine Inc. and Selvita SA extended their collaboration to develop precision medicines for cancer through September 2016.

Insys Therapeutics Inc. partnered with Senzer Ltd. for the development of inhaled synthetic pharmaceutical cannabinoid products.

Kinemed Inc. entered an agreement with Biopharma Forest Inc. to develop and commercialize synthetic ghrelin.

MRC Technology and the University of Lausanne are collaborating to find new drug treatments for diffuse large B-cell lymphoma.

Q Biomed Inc. intends to in-license and ultimately acquire the assets of Mannin Research Inc., which is developing a new class of vascular therapeutics.

Regeneron Pharmaceuticals Inc. entered an agreement with the BARDA to develop a monoclonal antibody therapy to treat Ebola virus infection.

Zai Lab Ltd. licensed a large molecule asset, with potential in both oncology and autoimmune diseases, from UCB SA.

Zedira GmbH and Cardiff University initiated a project addressing questions regarding the role of the transglutaminase 6 enzyme in the pathophysiology of neurodegenerative diseases.

. . . AND MORE

Acelrx Pharmaceuticals Inc. said the European Commission approved Zalviso for the management of acute moderate to severe postoperative pain in adult patients.

Alcobra Ltd. said the FDA has granted fast-track designation to Metadoxine extended-release for the treatment of Fragile X syndrome.

The EMA has opened a public consultation on the use of digital sensors embedded within pills to measure adherence and physiologic response, after concluding this form of tracking should be given its seal of approval as a biomarker in clinical trials.

The UK's Human Embryology and Fertilization Authority has received the first application for a license to use the precise genome editing tool CRISPR/Cas9 in human embryo research.